ABT

Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average-risk adults aged 45 and older, to be used every three years. The guidelines, combined with real-world data showing Cologuard tests drove an estimated very large share of CRC screening participation growth between 2018 and 2021, underscore how Abbott’s screening platform and patient navigation...

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.

Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed […]

Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.

These beaten-down Dividend Kings, trading near their 2026 lows, offer income, rebound potential, and Wall Street-backed upside for patient investors.

ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q1 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy declined 2.39% (net of fees), trailing the Russell 1000 Value Index’s 2.10%. The performance was positively affected by stock selection in industrials and consumer discretionary, along […]

Dividend growth among Kings accelerated to 3.71%, with notable increases from W.W. Grainger, Parker-Hannifin, and RLI Corp. Read more on Dividend Kings here.

If you are wondering whether Abbott Laboratories at around US$87.41 is a bargain or a value trap, it helps to step back and look at what the current price really implies. The stock has gained 3.5% over the past week, although it remains down 4.7% over the past month and has declined 29.6% year to date and 32.1% over the last year, which may have shifted how investors view its risk and potential reward. Recent coverage has focused on Abbott Laboratories as a large healthcare stock with a long...

If you are wondering whether Abbott Laboratories at around US$87.41 is a bargain or a value trap, it helps to step back and look at what the current price really implies. The stock has gained 3.5% over the past week, although it remains down 4.7% over the past month and has declined 29.6% year to date and 32.1% over the last year, which may have shifted how investors view its risk and potential reward. Recent coverage has focused on Abbott Laboratories as a large healthcare stock with a long...